MedTrace Logo

Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section

NCT02739815 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-06-15

No results posted yet for this study

Summary

This study aims to define a safe prophylactic intravenous TXA dose with an advantage over others in reducing total blood loss volume at secondary uncomplicated LSCS.

Conditions

  • Hemorrhage of Cesarean Section and/or Perineal Wound
  • Postpartum Hemorrhage

Interventions

DRUG

Normal Saline containing a prophylactic Antibiotic 1 g

500 ml of normal saline containing a prophylactic Antibiotic 1 g.

DRUG

Tranexamic Acid

Tranexamic acid

Sponsors & Collaborators

  • Al-Azhar University

    collaborator OTHER

  • Talkha Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Amro M. Hetta, MS Student · Al-Azhar University, Faculty of Medicine for boys (Cairo), Departments of OBS/GYN

  • Mahmoud E. Mohammed, Professor · Al-Azhar University, Faculty of Medicine for boys (Cairo), Departments of OBS/GYN

  • Yehia A. Wafa, Chairman · Al-Azhar University, Faculty of Medicine for boys (Cairo), Departments of OBS/GYN

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02739815 on ClinicalTrials.gov